VEGFA and Atrophy: Geographic atrophy has few effective therapeutic options, mainly based on complement C3 and C5 inhibitors (Pegcetacoplan and Avacincaptad pegol), while eAMD is primarily managed with intravitreal injections of anti-vascular endothelial growth factor (VEGF) agents such as bevacizumab, ranibizumab, aflibercept, brolucizumab, and faricimab [4,5,6].